Related Experiment Video
Updated: Jun 4, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and
Ottofianus Alvedo Hewick Kalangi1, Tioky Sutjonong1, Erica A Indrawan1
1Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Objective:
Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), the progesterone receptor (PR), or the human epidermal growth factor receptor 2 (HER2). TNBC has limited treatment targets, including the androgen receptor (AR). However, the therapeutic strategies-based AR expression in TNBC remains uncertain. The aim of this study is to compare the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus receptor-negative patients.
Methods:
A systematic search was performed through databases to search for cohort studies that compared the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus TNBC receptor-negative patients. The Mantel-Haenzel and Inverse Variance methods obtained a fixed-effects model of pooled odds or hazard ratios for the primary outcomes.
Results:
Fifteen cohort studies, including 2,713 patients with TNBC, were assessed. The effect of neoadjuvant chemotherapy is less superior on AR+ patients than AR- (OR = 0.60, p = 0.02). For survival outcomes, the AR+ subtype is associated with better 3-year DFS (HR = 0.93, p = 0.69) and 3-year OS (HR = 0.71, p = 0.20) compared with AR-. The statistical value is insignificant.
Conclusion:
The prognostic value of AR expression in TNBC is not fully understood, which is an inconclusive result.
Insights
Neoadjuvant chemotherapy may be less effective for androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) compared to AR-negative (AR-) TNBC. Survival outcomes for AR+ TNBC were not significantly different from AR- TNBC in this analysis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) lacks established treatment targets like estrogen receptor (ER), progesterone receptor (PR), or HER2.
- Androgen receptor (AR) is a potential therapeutic target in TNBC, but its role in treatment response is unclear.
Purpose of the Study:
- To compare the efficacy of neoadjuvant treatment in TNBC patients based on androgen receptor (AR) expression status (AR-positive vs. AR-negative).
Main Methods:
- A systematic review and meta-analysis of 15 cohort studies involving 2,713 TNBC patients.
- Pooled odds ratios (OR) and hazard ratios (HR) were calculated using fixed-effects models (Mantel-Haenzel and Inverse Variance methods).
Main Results:
- Neoadjuvant chemotherapy showed reduced efficacy in AR-positive (AR+) TNBC compared to AR-negative (AR-) TNBC (OR = 0.60, p = 0.02).
- No statistically significant differences were observed in 3-year disease-free survival (DFS) or overall survival (OS) between AR+ and AR- TNBC subtypes.
Conclusions:
- The prognostic significance of AR expression in TNBC remains uncertain.
- Further research is needed to fully elucidate the role of AR in TNBC treatment and prognosis.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
01:31Internal Receptors
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle